| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center [J. T. D., M. K., L. A. S., D. T. C.] and Medical Statistics Section, Division of Hematology and Oncology, Department of Medicine [D. E. C.], University of Alabama at Birmingham, Birmingham, Alabama 35294
Replicating adenoviruses (Ads) are designed to replicate in and destroy cancer cells, generating viral progeny that spread within the tumor. To address the importance of the primary cellular receptor for Ads, the coxsackievirus and Ad receptor (CAR), in permitting intratumoral spread of a replicating Ad, we have used a pair of tumor cell lines differing only in the expression of a primary receptor for Ad5. This novel system thus allowed the first direct evaluation of the relationship between the efficacy of a replicating Ad and the primary receptor levels of the host cell without the confounding influence of other variable cellular factors. We demonstrate that the absence of the primary cellular receptor on the tumor cells restricts the oncolytic potency of a replicating Ad both in vitro and in vivo. Based on these findings, it is apparent that the potential therapeutic advantages afforded by viral replication would be negated by poor intratumoral spread of the viral progeny due to the failure to infect neighboring tumor cells. Because a number of studies have reported that primary cancer cells express only low levels of CAR, our results suggest that strategies to redirect Ads to achieve CAR-independent infection will be necessary to realize the full potential of replicating Ads in the clinical setting.
This article has been cited by other articles:
![]() |
K. Matthews, P. E. Noker, B. Tian, S. D. Grimes, R. Fulton, K. Schweikart, R. Harris, R. Aurigemma, M. Wang, M. N. Barnes, et al. Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer Clin. Cancer Res., June 15, 2009; 15(12): 4131 - 4137. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ketola, A. Hinkkanen, F. Yongabi, P. Furu, A.-M. Maatta, T. Liimatainen, R. Pirinen, M. Bjorn, T. Hakkarainen, K. Makinen, et al. Oncolytic Semliki Forest Virus Vector as a Novel Candidate against Unresectable Osteosarcoma Cancer Res., October 15, 2008; 68(20): 8342 - 8350. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Gaballah, A. Hills, D. Curiel, G. Hallden, P. Harrison, and M. Partridge Lysis of Dysplastic but not Normal Oral Keratinocytes and Tissue-Engineered Epithelia with Conditionally Replicating Adenoviruses Cancer Res., August 1, 2007; 67(15): 7284 - 7294. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Van Houdt, H. Wu, J. N. Glasgow, M. L. Lamfers, C. M. Dirven, G. Y. Gillespie, D. T. Curiel, and Y. S. Haviv Gene delivery into malignant glioma by infectivity-enhanced adenovirus: In vivo versus in vitro models Neuro-oncol, July 1, 2007; 9(3): 280 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wakayama, M. Abei, R. Kawashima, E. Seo, K. Fukuda, H. Ugai, T. Murata, N. Tanaka, I. Hyodo, H. Hamada, et al. E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers Clin. Cancer Res., May 15, 2007; 13(10): 3043 - 3050. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tsuruta, L. Pereboeva, J. N. Glasgow, D. T. Rein, Y. Kawakami, R. D. Alvarez, R. P. Rocconi, G. P. Siegal, P. Dent, P. B. Fisher, et al. A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor Independent Pathway Clin. Cancer Res., May 1, 2007; 13(9): 2777 - 2783. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bourbeau, C. J. Lau, J. Jaime, Z. Koty, S. P. Zehntner, G. Lavoie, A.-M. Mes-Masson, J. Nalbantoglu, and B. Massie Improvement of Antitumor Activity by Gene Amplification with a Replicating but Nondisseminating Adenovirus Cancer Res., April 1, 2007; 67(7): 3387 - 3395. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rajecki, A. Kanerva, U.-H. Stenman, M. Tenhunen, L. Kangasniemi, M. Sarkioja, M. Y. Ala-Opas, H. Alfthan, A. Sankila, E. Rintala, et al. Treatment of prostate cancer with Ad5/3{Delta}24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo Mol. Cancer Ther., February 1, 2007; 6(2): 742 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-C. Pong, R. Roark, J.-Y. Ou, J. Fan, J. Stanfield, E. Frenkel, A. Sagalowsky, and J.-T. Hsieh Mechanism of Increased Coxsackie and Adenovirus Receptor Gene Expression and Adenovirus Uptake by Phytoestrogen and Histone Deacetylase Inhibitor in Human Bladder Cancer Cells and the Potential Clinical Application. Cancer Res., September 1, 2006; 66(17): 8822 - 8828. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kangasniemi, T. Kiviluoto, A. Kanerva, M. Raki, T. Ranki, M. Sarkioja, H. Wu, F. Marini, K. Hockerstedt, H. Isoniemi, et al. Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3137 - 3144. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Mathis, P. L. Stewart, Z. B. Zhu, and D. T. Curiel Advanced Generation Adenoviral Virotherapy Agents Embody Enhanced Potency Based upon CAR-Independent Tropism. Clin. Cancer Res., May 1, 2006; 12(9): 2651 - 2656. [Full Text] [PDF] |
||||
![]() |
M. D. Lacher, M. I. Tiirikainen, E. F. Saunier, C. Christian, M. Anders, M. Oft, A. Balmain, R. J. Akhurst, and W. M. Korn Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition Cancer Res., February 1, 2006; 66(3): 1648 - 1657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kesmodel, I. Prabakaran, R. Canter, C. Menon, K. Molnar-Kimber, and D. Fraker Virus-Mediated Oncolysis of Thyroid Cancer by a Replication-Selective Adenovirus Driven by a Thyroglobulin Promoter-Enhancer Region J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3440 - 3448. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Rein, M. Breidenbach, T. O. Kirby, T. Han, G. P. Siegal, G. J. Bauerschmitz, M. Wang, D. M. Nettelbeck, Y. Tsuruta, M. Yamamoto, et al. A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1327 - 1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Kirby, A. Rivera, D. Rein, M. Wang, I. Ulasov, M. Breidenbach, M. Kataram, J. L. Contreras, C. Krumdieck, M. Yamamoto, et al. A Novel Ex vivo Model System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity Clin. Cancer Res., December 15, 2004; 10(24): 8697 - 8703. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Merrill, G. Bernhardt, J. H. Sampson, C. J. Wikstrand, D. D. Bigner, and M. Gromeier Poliovirus receptor CD155-targeted oncolysis of glioma Neuro-oncol, July 1, 2004; 6(3): 208 - 217. [Abstract] [PDF] |
||||
![]() |
J. Davydova, L. P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment Cancer Res., June 15, 2004; 64(12): 4319 - 4327. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Gu, A. Ogose, H. Kawashima, M. Ito, T. Ito, A. Matsuba, H. Kitahara, T. Hotta, K. Tokunaga, H. Hatano, et al. High-Level Expression of the Coxsackievirus and Adenovirus Receptor Messenger RNA in Osteosarcoma, Ewing's Sarcoma, and Benign Neurogenic Tumors among Musculoskeletal Tumors Clin. Cancer Res., June 1, 2004; 10(11): 3831 - 3838. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Toth, H. Djeha, B. Ying, A. E. Tollefson, M. Kuppuswamy, K. Doronin, P. Krajcsi, K. Lipinski, C. J. Wrighton, and W. S. M. Wold An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling Cancer Res., May 15, 2004; 64(10): 3638 - 3644. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-C. Pong, Y.-J. Lai, H. Chen, T. Okegawa, E. Frenkel, A. Sagalowsky, and J.-T. Hsieh Epigenetic Regulation of Coxsackie and Adenovirus Receptor (CAR) Gene Promoter in Urogenital Cancer Cells Cancer Res., December 15, 2003; 63(24): 8680 - 8686. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fukuda, M. Abei, H. Ugai, E. Seo, M. Wakayama, T. Murata, T. Todoroki, N. Tanaka, H. Hamada, and K. K. Yokoyama E1A, E1B Double-restricted Adenovirus for Oncolytic Gene Therapy of Gallbladder Cancer Cancer Res., August 1, 2003; 63(15): 4434 - 4440. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kawakami, H. Li, J. T. Lam, V. Krasnykh, D. T. Curiel, and J. L. Blackwell Substitution of the Adenovirus Serotype 5 Knob with a Serotype 3 Knob Enhances Multiple Steps in Virus Replication Cancer Res., March 15, 2003; 63(6): 1262 - 1269. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al. Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors Cancer Res., August 1, 2002; 62(15): 4273 - 4281. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Bauerschmitz, J. T. Lam, A. Kanerva, K. Suzuki, D. M. Nettelbeck, I. Dmitriev, V. Krasnykh, G. V. Mikheeva, M. N. Barnes, R. D. Alvarez, et al. Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus Cancer Res., March 1, 2002; 62(5): 1266 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Vorburger and K. K. Hunt Adenoviral Gene Therapy Oncologist, February 1, 2002; 7(1): 46 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hemminki, I. Dmitriev, B. Liu, R. A. Desmond, R. Alemany, and D. T. Curiel Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule Cancer Res., September 1, 2001; 61(17): 6377 - 6381. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |